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ORIGINAL ARTICLE
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ABSTRACT Objectives: To evaluate the characteristics and work-up of small to intermediate-sized pulmonary nodules in a Chinese dedicated 
cancer hospital.
Methods: Patients with pulmonary nodules 4–25 mm in diameter detected via computed tomography (CT) in 2013 were 
consecutively included. The analysis was restricted to patients with a histological nodule diagnosis or a 2-year follow-up period 
without nodule growth confirming benign disease. Patient information was collected from hospital records.
Results: Among the 314 nodules examined in 299 patients, 212 (67.5%) nodules in 206 (68.9%) patients were malignant. 
Compared to benign nodules, malignant nodules were larger (18.0 mm vs. 12.5 mm, P < 0.001), more often partly solid (16.0% 
vs. 4.7%, P < 0.001) and more often spiculated (72.2% vs. 41.2%, P < 0.001), with higher density in contrast-enhanced CT (67.0 
HU vs. 57.5 HU, P = 0.015). Final diagnosis was based on surgery in 232 out of 314 (73.9%) nodules, 166 of which were identified 
as malignant [30 (18.1%) stage III or IV] and 66 as benign. In 36 nodules (11.5%), diagnosis was confirmed by biopsy and the 
remainder verified based on stability of nodule size at follow-up imaging (n = 46, 14.6%). Among 65 nodules subjected to gene 
(EGFR) mutation analyses, 28 (43.1%) cases (EGFR19 n = 13; EGFR21 n = 15) were identified as EGFR mutant and 37 (56.9%) as 
EGFR wild-type. Prior to surgery, the majority of patients [n = 194 (83.6%)] received a contrast-enhanced CT scan for staging of 
both malignant [n = 140 (84.3%)] and benign [n = 54 (81.8%)] nodules. Usage of positron emission tomography (PET)-CT was 
relatively uncommon [n = 38 (16.4%)].
Conclusions: CT-derived nodule assessment assists in diagnosis of small to intermediate- sized malignant pulmonary nodules. 
Currently, contrast-enhanced CT is commonly used as the sole diagnostic confirmation technique for pre-surgical staging, often 
resulting in surgery for late-stage disease and unnecessary surgery in cases of benign nodules.
KEYWORDS Lung nodule; diagnosis; computed tomography; pathology; China
Introduction
Lung cancer is the leading cause of tumor-associated mor-
tality in China owing to diagnosis and treatment at relatively 
advanced stages1. Early detection, in combination with early 
resection of malignant pulmonary nodules, has the potential 
to improve lung cancer outcomes2-4.
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With the widespread usage of low-dose multidetector 
computed tomography (CT), increasing numbers of small 
to intermediate-sized (mean diameter, 4 to 25 mm) pulmo-
nary nodules have been detected, the majority of which are 
benign. Based on three rounds of screening in the National 
Lung Screening Trial (NLST)5, 96.4% of the findings (nod-
ules > 4 mm) were false-positive. In a clinical setting, 
patients usually present with symptoms and larger-sized 
lung nodules (and masses)6-8. Due to differences in risk 
stratification, different management guidelines for nodules 
detected in lung cancer screening and clinical settings may 
be necessary.
In the past few years, considerable research attention has 
focused on optimizing management of pulmonary nodules 
detected in lung cancer screening sessions. The majority of 
these studies have investigated clinical diagnostic manage-
ment within Western populations8,9. However, lung cancer 
types, genetic susceptibility and environmental factors are 
significantly different between Asian and Western popu-
lations. For instance, East Asian lung cancer patients, pre-
dominantly non-smokers with adenocarcinoma, have a 
much higher  prevalence of epidermal growth factor receptor 
(EGFR)  mutation than their Western counterparts (~30% 
and 7%, respectively)10. The potential influence of these dif-
ferences on  nodule characteristics and management is largely 
unknown.
In the current study, we have reviewed the clinical charac-
teristics and work-up of small to intermediate-sized pulmo-
nary nodules of patients admitted to a large dedicated cancer 
hospital in Northern China.
Materials and methods
Study population
The study was conducted at the Tianjin Medical University 
Cancer Institute and Hospital (TJMUCH), one of the most 
important specialized cancer centers in Northern China, 
which treats thousands of lung cancer patients each year. 
A consecutive search was performed using the PACS database 
on patients at TJMUCH receiving chest CT scans in 2013. 
The following inclusion criteria were applied: 1) all pulmo-
nary nodules were newly detected in 2013 and 2) nodule 
diameters ranged from 4 to 25 mm. The final diagnosis of 
nodule nature (malignant or benign) was confirmed based on 
histological results or follow-up. Additionally, nodules were 
considered benign when they had disappeared, reduced in 
size by at least 30% or remained stable for at least 2 years on 
CT follow-up11. Exclusion criteria were as follows: 1) patients 
with suspected metastatic disease based on chest CT or his-
topathological findings and 2) nodules with unconfirmed 
results (for instance, no histology and inadequate follow-up 
period). Data on patients, nodules and clinical characteristics 
were collected from the hospital information system. Basic 
patient data included: 1) gender; 2) age; 3) smoking history; 
4) cancer history; 5) family cancer history. Information on 
nodule  characteristics included: 1) location (upper, middle or 
lower lobe ); 2) size (average value of maximum long  diameter 
and short diameter measured in the lung window); 3) shape 
(round, oval, irregular); 4) margin (smooth, lobulated, 
 spiculated); 5) nodule type (non-solid, part-solid, solid); 
6) density (attenuation value of the largest region of interest). 
Details of the assessment are described in Supplementary 
Figure S1–S5. Clinical characteristics included: 1) clinical 
diagnostic examination (CT, PET-CT, and biopsy); 2)  surgery 
characteristics; 3) pathology results; (4) gene mutation 
information.
CT protocol
Chest CT examinations were conducted using a Discovery 
CT750 HD (GE Medical Systems, Milwaukee, WI), 
Lightspeed 16 (GE Medical Systems) or Somatom Sensation 
64 (Siemens Medical Solutions, Forchheim, Germany) CT 
system. The CT examination encompassed regions ranging 
from the pulmonary apex level to below the diaphragm. 
For scanning, tube voltage of 120 kVp with automatic 
tube  current modulation was applied. For the GE CT sys-
tem, reconstructed slice thickness and pitch were 1.25 mm 
and 0.984, respectively. For the Siemens CT system, recon-
structed slice thickness and pitch were 1.5 mm and 0.95, 
respectively. The first CT examination was generally a 
non-contrast- enhanced CT. For further nodule evaluation, 
contrast- enhanced CT usually was performed at a later 
time. For contrast-enhanced CT, the iodine contrast agent 
Visipaque (Iodixanol, 270 mg/mL) was administered at a 
concentration of 1.5 mL/kg and injection rate of 2.5 mL/s. 
Contrast agents were administered intravenously through 
the upper extremity. Scanning was performed 70 s after the 
start of injection.
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Statistical analysis
Data are presented as numbers (%) for categorical variables. 
Pearson’s Chi-square test was used to examin differences in 
categorical variables between benign and malignant nodules. 
Normally distributed continuous data are presented as mean 
[standard deviation (SD)] and compared using Student’s 
t-test. Non-normally distributed continuous variables are pre-
sented as median [inter-quartile range (IQR)] and compared 
using a non-parametric test. P-values < 0.05 were indicative of 
statistical significance. All statistical analyses were performed 
using SPSS software version 20.0 (IBM, New York, US).
Results
Basic characteristics
In total, 491 patients with 609 primary pulmonary nodules 
fulfilled the inclusion criteria. Owing to lack of diagnostic 
confirmation, 295 nodules in 192 patients were excluded, 
leading to the final inclusion of 299 patients with 314 nodules 
for analysis. Out of the 299 patients, 206 (68.9%) were diag-
nosed with lung cancer (Figure 1). Within this patient group, 
75 (72.1%) men and 16 (15.7%) women were smokers at the 
time of the study. Among 65 nodules subjected to EGFR muta-
tion analysis, 13 (20%) were identified as EGFR19, 15 (23.1%) 
as EGFR21, and 37 (56.9%) as EGFR wild-type. Patient char-
acteristics are presented in Table 1.
Nodule evaluation
In total, 212 of the 314 small to intermediate-sized nodules 
were malignant (67.5%). CT characteristics are presented in 
Table 2. The majority of nodules were solid (n = 262, 83.4%), 
among which 168 (64.1%) were malignant, while 34 out of 
the 36 (94.4%) partly solid nodules were malignant. The max-
imum diameter of malignant nodules was 18.0 mm (median, 
IQR: 14.0–22.0 mm), which was significantly larger than that 
of benign nodules (median 12.5 mm, IQR: 9.0–18.0 mm). 
Nodule margins differed significantly between malignant 
and benign nodules. Malignant nodules often were spiculated 
[n = 153 (72.2%)] while 46 (45.1%) of the benign nodules 
were smooth (P < 0.001). Nodule densities of benign and 
malignant nodules detected using non- contrast enhanced 
CT were similar. However, malignant nodules detected with 
contrast- enhanced CT had significantly higher density [67.0 
HU (IQR: 51.0–81.0)] than benign nodules [57.5 HU (IQR: 
34.5–77.0, P = 0.015)] (Figure 2 and Figure 3).
Management and histopathological diagnosis 
of pulmonary nodules
Histopathological diagnosis was obtained for 268 out of 314 
(85.4%) nodules. In 232 (73.9%) cases, the nature of nodules 
was confirmed by surgery and 36 (11.5%) cases by biopsy. 
Table 3 presents an overview of nodule work-up. Among the 
102 benign nodules, 66 (64.7%) were confirmed by surgery, 
PACS
6,919 examinations
Newly detected pulmonary nodule in 2013
491 patients
(609 nodules)  




Follow-up cases: n = 4,606
Pulmonary metastasis: n = 970 
Diameter > 2.5 cm: n = 852
Nodule nature not confirmed: 295 
nodules in 192 patients (without 
histology, or less than 2 year 
follow-up)
Malignant
n = 206 (212 nodules)
Benign
n = 93 (102 nodules)
Figure 1 Flowchart of study population inclusion.
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Table 1 Patient characteristics
Characteristics   Total   Malignant   Benign   P
Gender, n (%)         0.803
 Male   153 (51.2)   104 (50.5)   49 (52.7)  
 Female   146 (48.8)   102 (49.5)   44 (47.3)  
Age in years, mean (SD)   57.7 (10.7)   59.5 (10.2)   53.6 (10.8)   <0.001
Smoking history*, n (%)         0.415
 Non smoker   157 (52.5)   112 (54.4)   45 (48.4)  
 Smoker   120 (40.1)   91 (44.2)   29 (31.2)  
Pack-year smoking history*, median (IQR)  45.0 (20.0–80.0)  45.0 (20.0–80.0)  22.5 (15.0–45.0)  0.039
Family cancer history*, n (%)         0.299
 No   225 (75.3)   168 (81.6)   57 (61.3)  
 Yes   52 (17.4)   35 (17.0)   17 (18.3)  
Clinical symptoms*, n (%)         0.342
 No   155 (51.8)   110 (53.4)   45 (48.4)  
 Yes   122 (40.8)   93 (45.1)   29 (31.2)  
COPD, n (%)         0.514
 No   247 (82.6)   168 (81.6)   79 (84.9)  
 Yes   52 (17.4)   38 (18.4)   14 (15.1)  
EGFR mutation        
 EGFR 19   13 (20.0)   13 (20.0)   -  
 EGFR 21   15 (23.1)   15 (23.1)   -  
 EGFR wild type   37 (56.9)   37 (56.9)   -  
*A total of 22 outpatients with no information on smoking, cancer history, family cancer history, and clinical symptoms. SD, standard 
deviation; IQR, interquartile range.
6 (5.9%) by biopsy, and 30 (29.4%) by stable size or resolution 
at CT follow-up. Nodules confirmed as benign by surgery were 
significantly larger than those determined as benign after CT 
follow-up (14.0 mm vs. 9.0 mm, respectively, P = 0.001).
Before surgery, the majority of patients only received a 
contrast-enhanced CT scan after an initial non-contrast CT 
scan for nodule staging in both malignant [n = 140 (84.3%)] 
and benign [n = 54 (81.8%)] cases. Thirty-two of the patients 
with confirmed malignancy (19.3%) underwent a PET-CT 
scan before surgery, 2 (1.2%) underwent biopsy before sur-
gery, and 12 (7.2%) underwent surgery immediately after the 
initial non-contrast CT scan. Among the resected lung can-
cers, 128 (77.1%) were diagnosed at stage I, 8 (4.8%) at stage 
II, 25(15.1%) at stage III, and 5 (3.0%) at stage IV (2 cases 
of pleural metastasis, 2 bone metastasis, 1 brain metastasis).
In total, 196 nodules were histologically confirmed as 
malignant. The majority of lung cancers were adenocarci-
nomas [n = 163 (83.2%)] and squamous cell carcinomas 
[n = 18 (9.2%)]. Among the 72 resected benign nodules, the 
most common histological diagnosis was hamartoma [n = 20 
(27.8%)]. Histopathological results are shown in Table 4.
Discussion
This study systematically describes the clinical characteristics 
and work-up of small to intermediate-sized primary pulmo-
nary nodules in a Chinese clinical population based on data 
from one of the leading cancer hospitals in North China. We 
evaluated pulmonary nodules based on patient, nodule, and 
clinical characteristics.
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Figure 2 Patient example 1. Male, 64 years, a solid spiculated nodule (13 mm * 11 mm) located on the right upper lobe with the pleural 
indentation sign. The mean density of the nodule was 16 Hounsfield Units on CT without iodine contrast, and uneven enhancement 97 
Hounsfield Units after contrast (A and B: non-contrast-enhanced CT. C: contrast-enhanced CT). Histology: Adenocarcinoma (stage I).
Table 2 CT characteristics of pulmonary nodules
Characteristics   Total   Malignant   Benign   P
Nodule type, n (%)         0.001
 Non-solid   16 (5.1)   10 (4.7)   6 (5.9)  
 Part-solid   36 (11.5)   34 (16.0)   2 (4.7)  
 Solid   262 (83.4)   168 (79.2)   94 (92.2)  
Nodule size (mm)         <0.001
 Median (IQR)   16.0 (12.0–20.0)   18.0 (14.0–22.0)  12.5 (9.0–18.0)  
Location, n (%)         0.886
 Upper lobe   178 (56.7)   122 (57.5)   56 (54.9)  
 Middle lobe   28 (8.9)   19 (9.0)   9 (8.8)  
 Lower lobe   108 (34.4)   71 (33.5)   37 (36.3)  
Margin, n (%)         <0.001
 Smooth   57 (18.2)   11 (5.2)   46 (45.1)  
 Lobulated   62 (19.7)   48 (22.6)   14 (13.7)  
 Spiculated   195 (62.1)   153 (72.2)   42 (41.2)  
Nodule density (HU), median (IQR)        
 CT density unenhanced   26.0 (15.0–34.0)   27.0 (20.0–34.5)  26.5 (15.0–35.0)   0.481
 CT density enhanced*   64.0 (47.0–80.0)   67.0 (51.0–81.0)  57.5 (34.5–77.0)   0.015
 Difference value*   38.0 (21.9–54.0)   42.0 (26.5–54.5)  28.0 (8.5–46.3)   0.001
*n = 76 without contrast-enhanced CT examination.
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Table 3 Diagnostic work-up of pulmonary nodules
Variable   Total   Malignant   Benign
Nodule nature confirmed by:      
 Surgery   232 (73.9)   166 (78.3)   66 (64.7)
 Biopsy   36 (11.5)   30 (14.2)   6 (5.9)
 CT follow-up   46 (14.6)   16 (7.5)   30 (29.4)
Procedure prior to surgery, n (%)      
 Contrast-enhanced CT   194 (83.6)   140 (84.3)   54 (81.8)
 CT FU   18 (7.8)   16 (9.6)   2 (3.0)
 PET CT   38 (16.4)   32 (19.3)   6 (9.1)
 Biopsy   2 (0.8)   2 (1.2)   0 (0.0)
 Only non-contrast enhanced CT   19 (8.2)   12 (7.2)   7 (10.6)
Stage of malignancy confirmed by surgery*, n (%)      
 I   -   128 (77.1)  
 II   -   8 (4.8)  
 III   -   25 (15.1)  
 IV   -   5 (3.0)  
*According to TNM 7th version.
Figure 3 Patient example 2. Female, 58 years, a solid smooth nodule (18 mm * 14 mm) located on the right upper lobe and close to the 
vessel. The mean density of the nodule was 41 Hounsfield Units on CT without iodine contrast, and uniform enhancement 52 Hounsfield Units 
after contrast (A and B: non-contrast-enhanced CT. C: contrast-enhanced CT). Histology: Hamartoma.
Patient characteristics
In our cohort, 67.5% of the clinically detected nodules were 
malignant. This lung cancer rate is obviously higher than 
that reported from community-based lung cancer screening 
using low-dose CT in China (malignancy rate between 0.6% 
and 1.5%)3,12,13. Moreover, relative to studies on other clinical 
cohorts, the percentage of malignant nodules in our analysis 
was considerably high9. This could be attributable to our hos-
pital being a dedicated cancer center to which most patients 
are referred because of suspicious nodules. In fact, 192 patients 
with 295 nodules were excluded owing to unconfirmed 
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diagnosis (Figure 1). We lost contact with patients once they 
left our hospital, which presents a major problem in the long-
term management of patients with pulmonary nodules in 
China.
Mean age at lung cancer diagnosis was similar to that 
reported in an earlier Chinese multi-institutional registry 
(CMIR) study (59.5±10.2 vs. 58.9±10.7)3. Smoking is the 
main cause of lung cancer, accounting for 80% of the male 
lung cancer burden and at least 50% of the female lung cancer 
burden worldwide14. However, in China, more than 30% of 
patients with lung cancer are non-smokers15-17. In our cohort, 
the proportion of smokers among female patients (15.7%) was 
substantially lower than that among male patients (72.1%). 
Several studies suggest second- hand  smoking and gene muta-
tions are risk factors for lung  cancer in female non-smok-
ers18-20. The EGFR mutation rate in our study was > 43%, 
which was significantly higher than that recorded in the 
Western population (approximately 7%)10.
CT evaluation of pulmonary nodules
Radiologists generally estimate lung cancer probability on the 
basis of nodule CT characteristics. In our study, partly solid 
nodules showed a high probability of malignancy (94.4%), 
consistent with data from earlier screening studies21-23. For 
solid nodules, pre-surgical diagnosis was usually based on 
contrast-enhanced CT. Malignant nodules generally showed 
a large density difference between contrast-enhanced and 
non-enhanced CT, which was negligible or smaller for benign 
nodules. In our patients, contrast enhancement on CT was one 
of the most important differentiators of malignant and benign 
nodules before surgery.
Nodule margin is another important feature in determin-
ing nodule malignancy risk. Malignant nodules tend to be 
 spiculated and lobulated while benign nodules are more likely 
to be smooth. In our cohort, 5.0% of malignant nodules were 
smooth, 22.6% were lobulated and 72.2% spiculated (P < 
0.001, compared to margins of benign nodules). Similar find-
ings have been reported previously24-27.
Nodule diagnosis and management
One of the most important objectives of nodule work-up 
is to diagnose malignant nodules as rapidly and accu-
rately as possible while minimizing the number of surgi-
cally removed benign nodules and late-stage lung cancers. 
Among the 232 resected nodules, 166 (71.6%) were malig-
nant and 66 (28.4%) were benign. Only 19.3% lung cancer 
patients in our study underwent PET-CT prior to surgery, 
which is significantly lower than previous reports (55.0%)9. 
Instead, multiple body part CT and MRI scans were often 
performed for staging. Thus contrast- enhanced CT was the 
main imaging examination technique employed prior to 
surgery. This is consistent with work-up guidelines in China 
based on expert opinions, the Diagnosis and Treatment for 
Lung Nodules (2016 Version)21, which provides a choice 
of contrast-enhanced CT, PET-CT, and biopsy. Among the 
benign nodules, only 30 (29.4%) were examined using CT 
follow-up in our study. The percentage of resected benign 
nodules was high, since 59 (57.8%) of all benign nodules 
were considered high risk according to the China National 
Guideline of Classification21. Furthermore, the diameters of 
resected benign nodules were generally larger than 10 mm. 
Considering the relatively high resection rates of benign nod-
ules and late-stage lung cancers (stage III or IV) in our study, 
it appears essential to refine the diagnostic process by using 
PET-CT to avoid unnecessary surgery. At the same time, 
excessive application of PET-CT will increase the financial 
burden for patients. To reach a compromise, more clinical 
Table 4 Histopathology results
Characteristics Pathology No. of 
nodules (%)











Malignant (n = 196)* Adenocarcinoma 163 (83.2)
Squamous cell 18 (9.2)
Small cell 5 (2.6)
Large cell 1 (0.5)
Carcinoid 3 (1.5)
Clear cell 1 (0.5)
*Detailed information on histopathologic subtype was missing for 
5 malignant and 8 benign nodules.
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research and expert consensus are required for optimization 
of future guidelines for China.
Our study population may reflect a high degree of selection 
bias, since our patients were sourced from a dedicated cancer 
hospital, with most being referred due to suspicion of malig-
nant nodules. In addition, we only included patients with 
available pathology results or more than 2 years of follow-up. 
Several patients with small nodules that were considered 
benign did not receive imaging follow-up in our center and 
were therefore excluded. These factors may explain the rela-
tively high rate of malignancy in our study population relative 
to other studies. Our data did not include patient information 
on ‘second-hand smoking’ and therefore, the effect of passive 
smoking was not estimated. Moreover, the current report is 
based on retrospective analysis of patient data from a single 
center and a multicenter prospective study is lacking.
Conclusions
In conclusion, this study systematically describes the 
 characteristics and work-up of clinically detected small to inter-
mediate-sized pulmonary nodules in a Chinese population. 
CT-derived nodule features effectively assisted in diagnosis of 
malignant pulmonary nodules. Pre-surgery lung cancer risk esti-
mation and staging are largely dependent on contrast- enhanced 
CT. PET-CT and biopsy were infrequently used for pre-surgi-
cal examination, which may explain the  relatively high rate of 
resected late-stage lung cancers and benign  nodules. Future 
research should focus on improvement of long-term manage-
ment of patients with pulmonary nodules and follow-up strate-
gies along with optimization of preoperative work-up.
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